吡啶并[2,3-d]嘧啶-2(1H)-一,6-氟-7-(2-氟-6-羟基苯基)-1-[4-甲基-2-(1-甲基乙基)-3-吡啶基]-4-[(2S)-2-甲基-4-(1-氧代-2-丙烯-1-基)-1-哌嗪基]-,(1R)-

吡啶并[2,3-d]嘧啶-2(1H)-一,6-氟-7-(2-氟-6-羟基苯基)-1-[4-甲基-2-(1-甲基乙基)-3-吡啶基]-4-[(2S)-2-甲基-4-(1-氧代-2-丙烯-1-基)-1-哌嗪基]-,(1R)-（CAS 2252403-56-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy. It is additionally approved in combination with [panitumumab] for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior [fluorouracil]-, [oxaliplatin]- and [irinotecan]-based chemotherapy.Sotorasib is a small molecule inhibitor of the KRAS G12C mutant protein which is found in up to 13% of refractory cases of non-small cell lung cancer. Serum aminotransferase elevations are common during therapy with sotorasib, and a proportion of patients develop clinically apparent liver injury that can be severe.

同义词与商品名

Sotorasib; AMG-510; 2296729-00-3; AMG510; Lumakras; AMG 510; Kras G12C inhibitor 9; Kras mutant-targeting AMG 510; 2B2VM6UC8G; CHEBI:178199; RefChem:56869; 2252403-56-6; AMG-510 racemate; SOTORASIB RACEMATE; Lumykras; Sotorasib [INN]

公开数据库对它的描述

Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)- · CAS 2252403-56-6 · C30H30F2N6O3. UNII 2B2VM6UC8G. Solubility: 1.3; Dissociation Constants: 8.06, 4.56.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。